Contact Us
Drug Search Results
More Filters [+]

Ketorolac

Alternative Names: ketorolac, ketoralac, acular, acuvail, sprix, toradol, ket-10, ket10, ket 10, omidria, acunistat-30, acunistat-60, acunivive 30, acunivive 15, acunivive 60, acunivive 90
Latest Update: 2024-12-11
Latest Update Note: Clinical Trial Update

Product Description

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID). Ketorolac works by reducing hormones that cause inflammation and pain in the body. (Sourced from: https://www.uofmhealth.org/health-library/d00273a1)

Mechanisms of Action: COX1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Pain Unspecified | Miosis | Pain Unspecified | Pain, Postoperative | Cataract

Known Adverse Events: Bradycardia | Hypertension | Oliguria | Rhinitis | Inflammation | Capsule Opacification

Company: Zyla Life Sciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ketorolac

Countries in Clinic: Australia, Belgium, China, Germany, Italy, Russia, Spain, Ukraine, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Pain, Postoperative

Phase 2: Breast Cancer|Conjunctivitis, Bacterial

Phase 1: Acute Pain|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
KePreSt

P2

Not yet recruiting

Breast Cancer

2026-07-20

NOV-1776-CL-101

P1

Not yet recruiting

Acute Pain

2024-12-01

NTM-001-CT001

P3

Completed

Pain, Postoperative

2024-09-06

MIRAKLE

P2

Completed

Conjunctivitis, Bacterial

2023-06-14

Recent News Events

Date

Type

Title

11/05/2024

News Article

 New Study Compares Caldolor® (ibuprofen injection) to ketorolac

10/25/2024

News Article

 Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

07/10/2024

News Article

 Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

02/01/2024

News Article

 DRI Healthcare Trust Announces the Expansion of its Royalty Entitlement on the US Net Sales of Omidria®, Updates Deployment and CAGR Guidance

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions